Tumor-derived hyaluronidase: A diagnostic urine marker for high-grade bladder cancer

Cancer Research

Volumn 57, Issue 4, 1997, Pages 778-783

  Pham, Henri T ^a   Block, Norman L ^a   Lokeshwar, Vinata B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIDASE; TUMOR MARKER;

ANGIOGENESIS; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER INVASION; CELL CYCLE G1 PHASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; LAMINA PROPRIA; MARKER GENE; PRIORITY JOURNAL;

ADULT; AGED; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYALURONOGLUCOSAMINIDASE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0031059785     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Heney, N. M. Natural history of superficial bladder cancer. Urol. Clin. North Am., 19: 429-435, 1992.
2. Jordan, A. M., Weingarten, J., and Murphy, W. M. Transitional cell neoplasms of the urinary bladder: can biologic potential be predicted from histological grading? Cancer (Phiia.), 60: 2766-2774, 1987.
3. Soloway, M. S. The management of superficial bladder cancer. Cancer (Phila.), 45: 1856-1865, 1980.
4. Murphy, W. M. Diseases of the urinary bladder, urethra, ureters and renal pelves. In: J. Whelan (ed.), Urological Pathology, pp. 34-146. Philadelphia: W. B. Saunders Co., 1989.
5. American Joint Committee on Cancer. Staging of cancer at genito-urinary sites. In: Manual for Staging Cancer, Ed. 3, pp. 194-195. Philadelphia: J. B. Lippincott Co., 1988.
6. Heney, N. M., and Flanagan, M. J. Superficial bladder cancer progression and recurrence. J. Urol., 130: 1083-1086, 1983.
7. Friedell, G. H., Soloway, M. S., Hilgar, A. G., and Farrow, G. M. Summary of workshop on carcinoma-m situ of the bladder. J. Urol., 136: 1047-1048, 1986.
8. Soloway, M. S. Invasive bladder cancer: selection of primary treatment. Semin. Oncol., 17: 551-554, 1990.
9. McCormick, B. A., and Zetter, B. R. Adhesive interactions in angiogenesis and metastasis. Pharmacol. Ther., 53: 239-260, 1992.
10. Laurent, T. C., and Fraser R. E. Hyaluronan. FASEB J., 6: 2397-2404, 1992.
11. Roden, L., Campbell, P., Fraser, R. E., Laurent, T. C., Petroff, H., and Thompson, J. N. Enzymatic pathways of hyaluronan catabolism. In: J. Whelan (ed.), The Biology of Hyaluronan, Ciba Foundation Symposium 143, pp. 60-86. New York: Wiley Chichister, 1989.
12. West, D. C., Hampson, I. N., Arnold, F., and Kumar, S. Angiogenesis induced by degradation products of hyaluronic acid. Science (Washington DC), 225: 1324-1326, 1985.
13. Gold, E. W. Purification and properties of hyaluronidase from human liver. Biochem. J., 205: 69-74, 1982.
14. Fraser, J. R. E., and Laurent, T. C. Turnover and metabolism of hyaluronan. In: J. Whelan (ed.), The Biology of Hyaluronan, Ciba Foundation Symposium 143, pp. 41-59. New York: Wiley Chichister, 1989.
15. Zhu, L., Hope, T. J., Hall, J., Davis, A., Stern, M., Muller-Eberhard, U., Stem, R., and Parslow, T. G. Molecular cloning of a mammalian hyaluronidase reveals identity with hemopexin, a serum heme-binding protein. J. Biol. Chem., 269: 32092-32097, 1994.
16. Lin, Y., Mahan, K., Lathrop, W. F., Meyers, D. G., and Primakoff, P. A hyaluronidase activity of the sperm plasma membrane protein PH-20 enables sperm to penetrate the cumulus layer surrounding the egg. J. Cell Biol., 125: 1157-1163, 1995.
17. Hobarth, K., Maier, U., and Marberger, M. Topical chemo-prophylaxis of superficial bladder cancer by mitomycin C and adjuvant hyaluronidase. Eur. Urol., 21: 206-210, 1992.
18. Knudson, W., Biswas, C., Li X-Q., Nemec, R. E., and Toole, B. P. The role and regulation of tumor-associated Hyaluronan. In: J. Whelan (ed.), The Biology of Hyaluronan, Ciba Foundation Symposium 143, pp. 150-169. New York: Wiley Chichester, 1989.
19. Lin, R. Y., Argenta, P. A., Sullivan, K. M., Stern, R., and Adzick, N. S. Urinary hyaluronic acid is a Wilms' tumor marker. J. Pediatr. Surg., 30: 304-308, 1995.
20. Stern, M., Longaker, M. T., Adzick, N. S., Harrison, M. R., and Stern, R. Hyaluronidase levels in urine from Wilms' tumor patients. J. Natl. Cancer Inst., 83: 1569-1574, 1991.
21. Lokeshwar, V. B., Lokeshwar, B. L., Pham, H. T., and Block, N. L. Association of hyaluronidase, a matrix-degrading enzyme with prostate cancer progression. Cancer Res., 56: 651-657, 1995.
22. Lokeshwar, V. B., Öbek, C., Soloway, M. S., and Block, N. L. Tumor-associated hyaluronic acid: a new sensitive and specific marker for bladder cancer. Cancer Res., 57: 773-777, 1997.
23. Gütenhoner, N. W., Pogrel, M. A., and Stem, R. Substrate gel assay for hyaluronidase activity. Matrix, 12: 388-396, 1992.
24. Tengblad, A. Affinity chromatography on immobilized hyaluronate and its application to the isolation of hyaluronate binding proteins from cartilage. Biochim. Biophys. Acta, 578: 281-289, 1979.
25. Stem, M., and Stem, R. An ELISA-like assay for hyaiuronidase and hyaluronidase inhibitor. Matrix, 12: 397-403, 1992.
26. Afify, A. M., Stem, M., Gütenhoner, M., and Stem, R. Purification and characterization of human serum hyaluronidase. Arch. Biochem. Biophys., 305: 434-441, 1993.
27. Salegui, M. D., Plonska, H., and Pigman, W. A comparison of serum and testicular hyaluronidase. Arch. Biochem. Biophys., 121: 548-554, 1967.
28. Pauli, B. U., and Knudson, W. Tumor invasion: a consequence of destructive and compositional matrix alterations. Hum. Pathol., 19: 628-639, 1988.
29. Wike-Hooley, J. L., Haveman, J., and Reinhold, H. S. The relevance of tumor pH to the treatment of malignant disease. Radiother. Oncol., 2: 343-366, 1984.
30. Thomas, L., Etoh, T., Stamenkovic, S., Mihm, M. C., and Byers, H. P. Migration of human melanoma cells on hyaluronate is related to CD44 expression. J. Invest. Dermatol., 100: 115-120, 1993.
31. Hopkins, S. C., Ford, K. S., and Soloway, M. S. Invasive bladder cancer: support for screening. J Urol., 130: 61-63, 1983.
32. Liu, B. C. S., and Liotta, L. A. Biochemistry of bladder cancer invasion and metastasis. Urol. Clin. North Am., 19: 621-627, 1992.
33. Messing, E. M., Young, T. B., Hunt, V. B., Newton, M. A., Bran, L. L., Vaillancourt, A., Hisgen, W. J., Greenberg, E. B., Kuglitsch, M. E., and Wegenke, J. D. Hematuria home screening: repeat testing results. J. Urol., 154: 57-61, 1995.
34. Britton, J. P., Dowell, A. C., Whelan, P., and Harris, C. M. A community study of bladder cancer screening by the detection of occult urinary bleeding. J. Urol., 148: 788-790, 1992.
35. Sarosdy, M. F., White, R. W., Soloway, M. S., Sheinfeld, J., Hudson, M. A., Schellhammer, P. F., Jarowenko, M. V., Adams, G., and Blumenstein, B. A. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J. Urol., 154: 379-384, 1995.
36. Soloway, M. S., Briggman, J. V., Carpinito, G. A., Chodak, G. W., Church, P. A., Lamm, D. L., Lange, P., Messing, E. M., Pasciak, R. M., Reservitz, G. B., Rukstalis, D. B., Sarosdy, M. F., Stadler, W. M., and Thiel, R. P. Use of a new tumor marker NMP22 in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J. Urol., 136: 363-367, 1996.